Vertex Pharmaceuticals Inc. / MA insider trading
In the last twelve months insiders at Vertex Pharmaceuticals Inc. / MA filed 55 open-market sales worth $71.9 million and 0 open-market purchases, on Form 4 with the SEC. The latest: Tatsis Ourania, EVP, Chief Reg. & Quality Off., sold 1,500 shares at $524.99 on 2 July 2026, filed 7 July 2026.
| Traded | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2 July 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sale | 1,500 | $524.99 | $787,485 | Form 4 |
| 2 July 2026 | Mckechnie Duncan | EVP, Chief Commercial Officer | Sale | 1,541 | $519.00 | $799,779 | Form 4 |
| 1 July 2026 | Liu Joy | EVP and Chief Legal Officer | Sale | 828 | $502.71 | $416,244 | Form 4 |
| 26 June 2026 | Bozic Carmen | EVP and CMO | Sale | 596 | $482.50 | $287,570 | Form 4 |
| 18 June 2026 | Bozic Carmen | EVP and CMO | Sale | 1,020 | $462.17 | $471,413 | Form 4 |
| 15 June 2026 | Bozic Carmen | EVP and CMO | Sale | 4,062 | $450.00 | $1.8 million | Form 4 |
| 5 June 2026 | Bozic Carmen | EVP and CMO | Sale | 1,745 | $450.00 | $785,250 | Form 4 |
| 1 June 2026 | Liu Joy | EVP and Chief Legal Officer | Sale | 828 | $439.91 | $364,245 | Form 4 |
| 29 May 2026 | Bozic Carmen | EVP and CMO | Sale | 1,974 | $450.00 | $888,300 | Form 4 |
| 15 May 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | Sale | 33 | $453.45 | $14,964 | Form 4 |
| 15 May 2026 | Bozic Carmen | EVP and CMO | Sale | 1,354 | $453.45 | $613,971 | Form 4 |
| 12 May 2026 | Bozic Carmen | EVP and CMO | Sale | 6,988 | $450.00 | $3.1 million | Form 4 |
| 4 May 2026 | Bhatia Sangeeta N. | Director | Sale | 318 | $423.73 | $134,746 | Form 4 |
| 1 May 2026 | Liu Joy | EVP and Chief Legal Officer | Sale | 1,104 | $425.02 | $469,222 | Form 4 |
| 1 April 2026 | Liu Joy | EVP and Chief Legal Officer | Sale | 978 | $449.17 | $439,288 | Form 4 |
| 27 March 2026 | Bozic Carmen | EVP and CMO | Sale | 2,329 | $450.95 | $1.1 million | Form 4 |
| 13 March 2026 | Bozic Carmen | EVP and CMO | Sale | 2,329 | $481.79 | $1.1 million | Form 4 |
| 11 March 2026 | Mckechnie Duncan | EVP, Chief Commercial Officer | Sale | 2,633 | $498.42 | $1.3 million | Form 4 |
| 4 March 2026 | Mckechnie Duncan | EVP, Chief Commercial Officer | Sale | 2,437 | $475.30 | $1.2 million | Form 4 |
| 2 March 2026 | Liu Joy | EVP and Chief Legal Officer | Sale | 892 | $495.96 | $442,396 | Form 4 |
| 27 February 2026 | Kewalramani Reshma | CEO & President | Sale | 400 | $479.75 | $191,900 | Form 4 |
| 27 February 2026 | Kewalramani Reshma | CEO & President | Sale | 120 | $481.50 | $57,780 | Form 4 |
| 27 February 2026 | Kewalramani Reshma | CEO & President | Sale | 240 | $482.84 | $115,882 | Form 4 |
| 27 February 2026 | Kewalramani Reshma | CEO & President | Sale | 2,510 | $487.13 | $1.2 million | Form 4 |
| 27 February 2026 | Kewalramani Reshma | CEO & President | Sale | 3,278 | $488.27 | $1.6 million | Form 4 |
| 27 February 2026 | Kewalramani Reshma | CEO & President | Sale | 460 | $489.32 | $225,087 | Form 4 |
| 27 February 2026 | Kewalramani Reshma | CEO & President | Sale | 2,725 | $490.54 | $1.3 million | Form 4 |
| 27 February 2026 | Kewalramani Reshma | CEO & President | Sale | 949 | $491.30 | $466,244 | Form 4 |
| 27 February 2026 | Kewalramani Reshma | CEO & President | Sale | 2,520 | $493.29 | $1.2 million | Form 4 |
| 27 February 2026 | Kewalramani Reshma | CEO & President | Sale | 3,498 | $494.33 | $1.7 million | Form 4 |
| 27 February 2026 | Kewalramani Reshma | CEO & President | Sale | 15,580 | $495.38 | $7.7 million | Form 4 |
| 27 February 2026 | Kewalramani Reshma | CEO & President | Sale | 5,995 | $496.16 | $3.0 million | Form 4 |
| 27 February 2026 | Kewalramani Reshma | CEO & President | Sale | 1,725 | $496.95 | $857,239 | Form 4 |
| 27 February 2026 | Bozic Carmen | EVP and CMO | Sale | 2,329 | $480.31 | $1.1 million | Form 4 |
| 26 February 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | Sale | 357 | $483.36 | $172,560 | Form 4 |
| 25 February 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sale | 260 | $486.35 | $126,451 | Form 4 |
| 25 February 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sale | 1,846 | $486.35 | $897,802 | Form 4 |
| 25 February 2026 | Mckechnie Duncan | EVP, Chief Commercial Officer | Sale | 2,500 | $486.35 | $1.2 million | Form 4 |
| 25 February 2026 | Mckechnie Duncan | EVP, Chief Commercial Officer | Sale | 2,410 | $489.00 | $1.2 million | Form 4 |
| 25 February 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | Sale | 620 | $486.35 | $301,537 | Form 4 |
| 25 February 2026 | Biller Jonathan | EVP and Chief Legal Officer | Sale | 945 | $486.35 | $459,601 | Form 4 |
| 25 February 2026 | Atkinson Edward Morrow Iii | EVP, Chief Technical Ops. Off. | Sale | 668 | $486.35 | $324,882 | Form 4 |
| 25 February 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | Sale | 223 | $486.35 | $108,456 | Form 4 |
| 19 February 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sale | 920 | $463.91 | $426,797 | Form 4 |
| 19 February 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sale | 2,730 | $465.05 | $1.3 million | Form 4 |
| 19 February 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sale | 1,848 | $465.80 | $860,798 | Form 4 |
| 19 February 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sale | 10,263 | $467.75 | $4.8 million | Form 4 |
| 19 February 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sale | 19,662 | $468.57 | $9.2 million | Form 4 |
| 19 February 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sale | 7,241 | $469.61 | $3.4 million | Form 4 |
| 19 February 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sale | 11,712 | $470.54 | $5.5 million | Form 4 |
| 19 February 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Sale | 4,237 | $471.43 | $2.0 million | Form 4 |
| 18 February 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sale | 368 | $473.68 | $174,314 | Form 4 |
| 18 February 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | Sale | 1,182 | $473.68 | $559,890 | Form 4 |
| 17 February 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Sale | 609 | $489.46 | $298,081 | Form 4 |
| 17 February 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | Sale | 2,437 | $489.46 | $1.2 million | Form 4 |
Open-market purchases (code P) and sales (code S) only. Option exercises, grants, tax withholding and gifts are not shown. A filing with several lines appears once per line.
Source
Form 4 filings on EDGAR for Vertex Pharmaceuticals Inc. / MA: the company's filing index.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.